DBV TECHNOLOGIES Aktie

1,30 EUR +0,29 EUR +28,71 %

19:55:18

FSE

1,13 EUR +0,05 EUR +4,26 %

31.03.2025

PAR

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.110,75 Mio. EUR

Div. Rendite0,00%

WKNA1JWB7

ISINFR0010417345

SymbolDBVTF

DBV TECHNOLOGIES Aktien News

Sortieren:Datum Meistgelesen

05.10.23GlobeNewswireMonthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2023

05.09.23GlobeNewswireDBV Technologies to Participate in Upcoming Investor Conference

31.07.23GlobeNewswireDBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results

25.07.23GlobeNewswireDBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update

19.07.23GlobeNewswireMonthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023

10.07.23GlobeNewswireHalf-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

16.06.23GlobeNewswireMonthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2023

08.06.23GlobeNewswireDBV Technologies to Participate in Upcoming EAACI Congress 2023

06.06.23GlobeNewswireDBV Technologies to Participate in Upcoming Investor Conference

10.05.23GlobeNewswireDBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers

09.05.23GlobeNewswireDBV Technologies to Participate in Upcoming Investor Conference

04.05.23GlobeNewswireDBV Technologies Reports First Quarter 2023 Financial Results

19.04.23GlobeNewswireDBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA

12.04.23GlobeNewswireDBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting

24.03.23GlobeNewswireOrdinary and Extraordinary General Meeting of April 12, 2023

13.03.23GlobeNewswireDBV Technologies Update

07.03.23GlobeNewswireDBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old

02.03.23GlobeNewswireDBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document

02.03.23GlobeNewswireDBV Technologies Reports Full Year 2022 Financial Results and Business Update

27.02.23GlobeNewswireDBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023

21.02.23GlobeNewswireDBV Technologies to Participate in Upcoming AAAAI 2023 Congress

10.02.23GlobeNewswireDBV Technologies to Participate in Upcoming Investor Conference

22.11.22GlobeNewswireDBV Technologies to Participate in Upcoming Investor Conference

09.11.22GlobeNewswireDBV Technologies to Highlight New Clinical Data at ACAAI 2022

03.11.22GlobeNewswireDBV Technologies Reports Third Quarter Financial Results and Business Update

31.10.22GlobeNewswireDBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update

20.10.22GlobeNewswireMonthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2022

11.10.22PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DBV Technologies S.A. - DBVT

03.10.22GlobeNewswireDBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors

03.10.22PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DBV Technologies S.A. - DBVT

21.09.22GlobeNewswireDBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial

07.09.22GlobeNewswireDBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years

02.09.22GlobeNewswireDBV Technologies to Present at Upcoming Investor Conferences

01.08.22GlobeNewswireDBV Technologies Reports Second Quarter 2022 Financial Results

27.07.22GlobeNewswireHalf-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

20.07.22GlobeNewswireMonthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2022

29.06.22GlobeNewswireDBV Technologies to Participate in Upcoming EAACI 2022 Congress

16.06.22GlobeNewswireDBV Technologies to Present at the JMP Securities Life Sciences Conference in New York

09.06.22GlobeNewswireDBV Technologies Announces Private Placement Financing of $194 Million

07.06.22GlobeNewswireDBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers

DBV TECHNOLOGIES News

DBV TECHNOLOGIES News: auf dieser Seite finden Sie alle DBV TECHNOLOGIES News und Nachrichten zur DBV TECHNOLOGIES Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch DBV TECHNOLOGIES News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um DBV TECHNOLOGIES News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.